What type of study is this?

September 10, 2025Lara D. Veeken

Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib

View Full Paper

Ask AI

Bookmark

Upadacitinib effectively reduces pain in patients with psoriatic arthritis, achieving a mean change in VAS pain of -31.4.
A total of 38.2% of patients attained ASDAS-LDA and 20.6% reached ASDAS-ID after 12 months of treatment.
Kaplan-Meier curves revealed a 12-month survival rate of 75.1% for upadacitinib, higher for peripheral psoriatic arthritis.
Fibromyalgia emerged as the strongest predictor of treatment discontinuation, highlighting a significant challenge in patient management.

No takes yet. Share an insight, caveat, or question.

Observational study shows upadacitinib improves low disease activity in psoriatic arthritis, indicating significant treatment benefits.

Lopalco et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark